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The fundamental changes to the 2014 American 
College of Cardiology and American Heart Association 
algorithm
There are seven fundamental changes to the 2014 ACC/AHA 
algorithm. These changes are dealt with sequentially, as they are 
presented in the pathway of the guideline.
Firstly, the identification of unstable cardiovascular conditions 
has changed in terminology from a more inclusion “active cardiac 
conditions” to more selective “acute coronary syndromes”.1 
The implications are that the new algorithm now places more 
emphasis on coronary artery disease1 at the expense of cardiac 
failure, valvular heart disease and arrhythmias.2 This is an 
important observation as we know that cardiac failure, valvular 
heart disease and significant arrhythmias are associated with 
increased cardiovascular risk. The algorithm that is now proposed 
should not be considered as an acceptable risk stratification 
approach to patients with cardiac failure, valvular heart disease 
and arrhythmias. 
The second change is that the guideline executive committee 
has removed surgical grading from the risk stratification. They 
have now integrated “surgical risk” into the recommended 
preoperative risk stratification model.2 Previously, low-risk 
surgery was essentially “a ticket to surgery”,2 but in the new 
algorithm, emphasis is placed on the predicted risk of major 
adverse cardiac events (MACE), irrespective of the surgical risk 
category. The implication is that low-risk surgery should undergo 
the same scrutiny for MACE risk as other surgeries. However, it 
must be remembered that the surgical risk is now built into the 
preoperative risk stratification models,3-5 and as such, only a very 
small proportion of patients undergoing low-risk surgery will be 
flagged as being at increased cardiac risk.
The third change is that the ACC and AHA now consider two 
cardiovascular risk stratification models to be acceptable in the 
determination of cardiovascular risk in addition to Lee’s Revised 
Cardiac Risk Index; namely Gupta’s model and the National 
Surgical Quality Improvement Program (NSQIP) model.4,5 It 
is important to note that neither the Gupta model nor the 
NSQIP model have been validated outside of the USA.4,5 The 
implication is that these models provide an acceptable estimate 
of cardiovascular risk within the USA population, and this is 
almost certainly driven by the more discriminatory surgical risk 
stratification built into these models. There is now indecision 
on what is the gold standard for preoperative cardiovascular 
risk stratification, and it can be assumed that the executive 
guidelines committee now believes that a more discriminating 
model is necessary. It would be reasonable to assume that the 
most discriminatory model for cardiovascular risk is deemed to 
be most desirable, and if we generated a locally relevant and 
discriminatory model for MACE in South Africa, it would be 
reasonable to adopt it for clinical practice.
The fourth change is that the ACC and AHA has now defined 
elevated cardiac risk as anyone with a risk of MACE > 1%. There 
is no further risk stratification once a patient is deemed to be at 
increased risk by this definition.1 The need for further noninvasive 
testing is now left to the clinician’s discretion once a patient has a 
MACE risk of > 1%.1 The clinician needs to decide to make a call as 
to whether or not further testing will impact on decision-making 
and the management of perioperative care. 
The fifth change is that pharmacological stress testing is now 
recommended, should further testing be clinically indicated.1 
This may be the result of the tighter focus of the algorithm 
on coronary artery disease now, and the suggestion that 
pharmacological stress testing may be a trend with respect to 
better performance for diagnosing and managing coronary 
artery disease.6 
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The sixth change is that positive pharmacological stress 
tests should be followed with a consideration for coronary 
revascularisation. This is strong support for the fact that in patients 
in whom coronary revascularisation is indicated prior to elective 
noncardiac surgery, there is evidence to suggest that they fare 
better if they receive preoperative coronary revascularisation, 
particularly in unprotected left main stem disease.7
The seventh fundamental change is that heart rate control has 
now been removed from the guidelines as a recommended 
routine risk reduction procedure in patients at increased risk.1 
This change acknowledges the controversy surrounding rate 
control with a beta blockade, and the associated positive and 
negative outcomes.8 
Conclusion
The new 2014 ACC and AHA guideline has a more focused 
approach to coronary artery disease now.1 The guideline 
suggests that all patients with a MACE risk of > 1% require an 
individualised approach to risk stratification and risk reduction.
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